Specifically, M2-type TAMs were characterized for the secretion of immune-modulating interleukins (IL-6, IL-8, and IL-10), which creates an immunosuppressive TME favorable for NSCLC growth and metastasis [522–524]. This evidence concerns the gene IL6 and non-small cell lung carcinoma.